Search Results
Search for other papers by Ramjan Sanas Mohamed in
Google Scholar
PubMed
Search for other papers by Biyaser Abuelgasim in
Google Scholar
PubMed
Search for other papers by Sally Barker in
Google Scholar
PubMed
Search for other papers by Hemanth Prabhudev in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Niamh M Martin in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Karim Meeran in
Google Scholar
PubMed
Search for other papers by Emma L Williams in
Google Scholar
PubMed
Search for other papers by Sarah Darch in
Google Scholar
PubMed
Search for other papers by Whitlock Matthew in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Tricia Tan in
Google Scholar
PubMed
Search for other papers by Florian Wernig in
Google Scholar
PubMed
Endogenous Cushing’s syndrome (CS) poses considerable diagnostic challenges. Although late-night salivary cortisol (LNSC) is recommended as a first-line screening investigation, it remains the least widely used test in many countries. The combined measurement of LNSC and late-night salivary cortisone (LNS cortisone) has shown to further improve diagnostic accuracy. We present a retrospective study in a tertiary referral centre comparing LNSC, LNS cortisone, overnight dexamethasone suppression test, low-dose dexamethasone suppression test and 24-h urinary free cortisol results of patients investigated for CS. Patients were categorised into those who had CS (21 patients) and those who did not (33 patients). LNSC had a sensitivity of 95% and a specificity of 91%. LNS cortisone had a specificity of 100% and a sensitivity of 86%. With an optimal cut-off for LNS cortisone of >14.5 nmol/L the sensitivity was 95.2%, and the specificity was 100% with an area under the curve of 0.997, for diagnosing CS. Saliva collection is non-invasive and can be carried out at home. We therefore advocate simultaneous measurement of LNSC and LNS cortisone as the first-line screening test to evaluate patients with suspected CS.